BioNTech’s Bold Strides Toward the Future: A Crucible of Innovation
BioNTech pivots from COVID-19 vaccine success towards mRNA-based cancer therapies. Despite a revenue decline to €2.75 billion, the company surpassed market forecasts in 2024. The company reported a net loss…